Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization

Mark S. Schmidt; Thomas E. Prisinzano; Kevin Tidgewell; Wayne Harding; Eduardo R. Butelman; Mary J. Kreek; Daryl J. Murry

doi:10.1016/j.jchromb.2004.12.041

Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization

Mark S. Schmidt
, Thomas E. Prisinzano
, Kevin Tidgewell
, Wayne Harding
, Eduardo R. Butelman
, Mary J. Kreek
, Daryl J. Murry

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Salvinorin A was quantitated in human and rhesus monkey plasma, rhesus monkey cerebrospinal fluid, and human urine by negative ion LC-MS/APCI. The method for Salvinorin A has been fully validated, the LLOQ using FDA guidelines is 2 ng/mL for 0.5 mL plasma samples. The linear range was from 2 to 1000 ng/mL. Several derivatives in the Salvinorin family can also be analyzed by this method; d₃-Salvinorin A was prepared and used as internal standard. The metabolite Salvinorin B can be semi quantitatively determined. The method has been used to establish that Salvinorin B is the principal metabolite of Salvinorin A ex vivo and to establish the analytical method to study in vivo samples.

Original language	English
Pages (from-to)	221-225
Number of pages	5
Journal	Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Volume	818
Issue number	2
DOIs	https://doi.org/10.1016/j.jchromb.2004.12.041
State	Published - Apr 25 2005

Bibliographical note

Funding Information:
Studies were supported in part by NIH-NIDA grants DA11113 (ERB) and DA05130 and DA00049 (MJK).

Funding

Studies were supported in part by NIH-NIDA grants DA11113 (ERB) and DA05130 and DA00049 (MJK).

Funders	Funder number
NIH/NIDA	DA05130, DA00049, DA11113
National Institute on Drug Abuse	P50DA005130
National Institute on Drug Abuse

Keywords

APCT
Analysis
Body fluids
LC-MS
Metabolism
Plasma
Salvinorin
Salvinorin A
Urine

ASJC Scopus subject areas

Analytical Chemistry
Biochemistry
Clinical Biochemistry
Cell Biology

Access to Document

10.1016/j.jchromb.2004.12.041

Cite this

Schmidt, M. S., Prisinzano, T. E., Tidgewell, K., Harding, W., Butelman, E. R., Kreek, M. J., & Murry, D. J. (2005). Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 818(2), 221-225. https://doi.org/10.1016/j.jchromb.2004.12.041

@article{7bb4441336b64792bcda5048a285eb65,

title = "Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization",

abstract = "Salvinorin A was quantitated in human and rhesus monkey plasma, rhesus monkey cerebrospinal fluid, and human urine by negative ion LC-MS/APCI. The method for Salvinorin A has been fully validated, the LLOQ using FDA guidelines is 2 ng/mL for 0.5 mL plasma samples. The linear range was from 2 to 1000 ng/mL. Several derivatives in the Salvinorin family can also be analyzed by this method; d3-Salvinorin A was prepared and used as internal standard. The metabolite Salvinorin B can be semi quantitatively determined. The method has been used to establish that Salvinorin B is the principal metabolite of Salvinorin A ex vivo and to establish the analytical method to study in vivo samples.",

keywords = "APCT, Analysis, Body fluids, LC-MS, Metabolism, Plasma, Salvinorin, Salvinorin A, Urine",

author = "Schmidt, \{Mark S.\} and Prisinzano, \{Thomas E.\} and Kevin Tidgewell and Wayne Harding and Butelman, \{Eduardo R.\} and Kreek, \{Mary J.\} and Murry, \{Daryl J.\}",

note = "Funding Information: Studies were supported in part by NIH-NIDA grants DA11113 (ERB) and DA05130 and DA00049 (MJK).",

year = "2005",

month = apr,

day = "25",

doi = "10.1016/j.jchromb.2004.12.041",

language = "English",

volume = "818",

pages = "221--225",

number = "2",

}

Schmidt, MS, Prisinzano, TE , Tidgewell, K, Harding, W, Butelman, ER, Kreek, MJ & Murry, DJ 2005, 'Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization', Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, vol. 818, no. 2, pp. 221-225. https://doi.org/10.1016/j.jchromb.2004.12.041

Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization. / Schmidt, Mark S.; Prisinzano, Thomas E.; Tidgewell, Kevin et al.
In: Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, Vol. 818, No. 2, 25.04.2005, p. 221-225.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization

AU - Schmidt, Mark S.

AU - Prisinzano, Thomas E.

AU - Tidgewell, Kevin

AU - Harding, Wayne

AU - Butelman, Eduardo R.

AU - Kreek, Mary J.

AU - Murry, Daryl J.

N1 - Funding Information: Studies were supported in part by NIH-NIDA grants DA11113 (ERB) and DA05130 and DA00049 (MJK).

PY - 2005/4/25

Y1 - 2005/4/25

N2 - Salvinorin A was quantitated in human and rhesus monkey plasma, rhesus monkey cerebrospinal fluid, and human urine by negative ion LC-MS/APCI. The method for Salvinorin A has been fully validated, the LLOQ using FDA guidelines is 2 ng/mL for 0.5 mL plasma samples. The linear range was from 2 to 1000 ng/mL. Several derivatives in the Salvinorin family can also be analyzed by this method; d3-Salvinorin A was prepared and used as internal standard. The metabolite Salvinorin B can be semi quantitatively determined. The method has been used to establish that Salvinorin B is the principal metabolite of Salvinorin A ex vivo and to establish the analytical method to study in vivo samples.

AB - Salvinorin A was quantitated in human and rhesus monkey plasma, rhesus monkey cerebrospinal fluid, and human urine by negative ion LC-MS/APCI. The method for Salvinorin A has been fully validated, the LLOQ using FDA guidelines is 2 ng/mL for 0.5 mL plasma samples. The linear range was from 2 to 1000 ng/mL. Several derivatives in the Salvinorin family can also be analyzed by this method; d3-Salvinorin A was prepared and used as internal standard. The metabolite Salvinorin B can be semi quantitatively determined. The method has been used to establish that Salvinorin B is the principal metabolite of Salvinorin A ex vivo and to establish the analytical method to study in vivo samples.

KW - APCT

KW - Analysis

KW - Body fluids

KW - LC-MS

KW - Metabolism

KW - Plasma

KW - Salvinorin

KW - Salvinorin A

KW - Urine

UR - https://www.scopus.com/pages/publications/14744300400

UR - https://www.scopus.com/pages/publications/14744300400#tab=citedBy

U2 - 10.1016/j.jchromb.2004.12.041

DO - 10.1016/j.jchromb.2004.12.041

M3 - Article

C2 - 15734162

AN - SCOPUS:14744300400

SN - 1570-0232

VL - 818

SP - 221

EP - 225

JO - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

JF - Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

IS - 2

ER -

Determination of Salvinorin A in body fluids by high performance liquid chromatography-atmospheric pressure chemical ionization

Abstract

Bibliographical note

Funding

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this